Share on

Middle East & Africa Parkinson’s Disease Treatment Market Research Report – Segmented By Drug Class, Distribution Channel, Patient Care Setting & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 7155
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the MEA Parkinson’s Disease Treatment Market was worth USD 0.46 billion in 2022 and estimated to be growing at a CAGR of 4.807%, to reach USD 0.58 billion by 2027.

Parkinson's disease is primarily symptomatic, with no curative therapeutic options available. The primary goal of Parkinson's disease treatment is to keep signs and symptoms, including shakiness in the hands, trouble walking, and slowness of movement under control. Each person's treatment strategy is unique to their symptoms.

The treatment market for Parkinson's disease is expected to grow due to increasing environmental variables and genetic inheritance in the MEA region. In addition, recent advancements in Parkinson's disease treatment, such as combination therapies to extend the action of continuous dopaminergic stimulation drugs, approval for Neurostimulation devices, neuroprotective therapies to slow disease prognosis, gene therapy, neural transplantation, and others, are expected to drive massive growth in the MEA Parkinson's disease treatment market over the forecast period.

Y-O-Y rise in the aging population, which is expected to be aided by the rising prevalence of Parkinson's disease and anticipated to accelerate the market's growth rate during the forecast period in this region. Increasing research and development investment results in creating novel treatments, which is expected to help the market expand. The demand for Parkinson's disease treatment will increase as people become more aware of viable treatments.

In addition, factors such as increasing advances in the creation of innovative pharmaceuticals and expanding health infrastructure in numerous MEA countries are expected to fuel market expansion in the future years. Furthermore, rising healthcare spending, driven by consumer demand for high-quality services, is likely to increase market expansion.

Parkinson's disease is a neurodegenerative disease that predominantly affects the human brain, making it difficult to function and carry out daily tasks. Parkinson's disease is characterized by a lack of dopamine production, which results in stiffness, tremors, and difficulty walking, among other symptoms. If not treated promptly, this condition can become quite serious. However, due to the pandemic's resource constraints and diversion, effective symptomatic therapy for Parkinson's disease is no longer available.

This research report on the Middle East & Africa Parkinson’s disease treatment market has been segmented and sub-segmented into the following categories:

By Drug Class: 

  • Dopamine Receptor Antagonists
    • Pramipexole
    • Ropinirole
    • Apomorphine
    • Rotigotine
  • Mono Amine Oxidase Inhibitors
    • Selegiline
    • Rasagiline
  • Carbidopa
  • Anticholinergics
  • Other Drug Classes

By Distribution Channels: 

  • Retailer Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Patient Care Setting:

  • Clinics
  • Hospitals 

By Country:

  • KSA
  • UAE
  • Israel
  • Rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • Rest of MEA

Geographically, the Middle East and Africa regional markets are forecasted to account for a moderate share of the global market during the forecast period. The growing burden of Parkinson's disease management on large countries' healthcare systems, such as the UAE and Kuwait, would encourage the government to make concerted efforts to accelerate R&D in Parkinson's disease therapy.

KEY MARKET PLAYERS:

Companies playing an influential role in the MEA Parkinson’s Disease Treatment Market profiled in the report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample